Pentagon gets blank check to reshape biotech for military use
H.R. 6009 — Defense Biotechnology Strategy Act · Filed by Chrissy Houlahan (D-PA) · 2 cosponsors · Introduced Nov 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Defense to develop a comprehensive strategy within one year on how biotechnology can serve national defense needs, including plans to build manufacturing capacity, update military specifications, commit to purchasing biotech products, and coordinate with NATO allies on biotech research and procurement. The strategy aims to position the U.S. military and defense industrial base to leverage emerging biotechnologies for military advantage.
Why we flagged it
The bill is fundamentally a directive to the DoD to create a strategy for integrating biotechnology into military operations and procurement. It is not a direct appropriation or regulatory change, but a planning mandate that will likely drive future defense spending and industry partnerships in the biotech sector.
What the text implies
- The bill's emphasis on 'advance market commitments' and 'offtake agreements' may lock the DoD into long-term contracts with biotech firms before products are fully tested or proven, reducing competitive pressure and potentially inflating costs.
- The mandate to 'simplify regulation' and develop 'digital infrastructure' for biotech approval may accelerate the pathway for military biotech applications with less civilian regulatory scrutiny, creating a two-track approval system.
The full analysis lists 5 implications of this text.
Who stands to gain
large pharmaceutical and biotech companies (Biogen, Bristol Myers Squibb, others mapped); defense contractors with biotech divisions; contract research organizations (CROs) serving defense